FDA Panel Says No More Avastin in Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 8
Volume 19
Issue 8

An FDA advisory panel has recommended that bevacizumab (Avastin) no longer be approved for use in patients with breast cancer.

An FDA advisory panel has recommended that bevacizumab (Avastin) no longer be approved for use in patients with breast cancer. As a condition of its 2008 approval, manufacturer Roche was required to conduct follow-up studies to show its benefits when used along with standard chemotherapy. The FDA advisory panel said that the two subsequent studies did not show the same magnitude of improvement as a previous study, E2100, which demonstrated a 5.5 month difference in median progression-free survival (PFS). One study (AVADO) observed 0.82 month and 0.88 month differences in median PFS while another study (RIBBON-1) observed a 1.2 month difference in median PFS.  Patients also reported significant side effects such as high blood pressure and fatigue.

The panel also stated that one of the follow-up studies failed to prove that the benefits of bevacizumab plus docetaxel (Taxotere) outweighed the risk associated with treatment. The FDA is scheduled to issue a final decision on September 17, 2010.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content